Deflazacort
Glucocorticoids
Sold as CAMIQUA
- Drug class
- Glucocorticoids
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 7
- FDA reports (12 mo)
- 235
Overview
Plain-language summary, compiled from the cited regulatory records
Deflazacort is a corticosteroid [1]. It belongs to the drug class of glucocorticoids [1].
Deflazacort oral suspension is approved for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 5 years and older [1].
In the past 12 months, there have been 235 adverse event reports for deflazacort [2]. The most frequently reported adverse events include off-label use, no adverse event, product dose omission issues, intentional dose omission, and nausea [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 2 | November 27, 2025 |
| GB United Kingdom | MHRA | 5 | March 6, 2026 |
USUnited States· FDA
2 products
Uses
1 INDICATIONS AND USAGE Deflazacort oral suspension is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. 's Emflaza™ (deflazacort) oral suspension. 's marketing exclusivity rights, this drug product is not labeled with that information .
Deflazacort oral suspension is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older ( 1 )
How to take
GBUnited Kingdom· MHRA
5 products
Drug interactions
Known interactions involving Deflazacort. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 340. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 14569f71-573e-49… · revised November 27, 2025 [PDF]
- [2]MHRA (UK) · PL167860008 · revised February 9, 2021
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.